$EVMN News
Last published 2d ago
- 2d agoEVMNEvommune to Present at Upcoming Investor ConferencesBusiness WirePALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced presentations by management at the following upcoming investor conferences:Stifel Healthcare Conference 2026 in New York: Fireside Chat on Wednesday, ...
- 1mo agoEVMNEvommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology CongressBusiness WirePresentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL-18 inhibition as a novel, clinically relevant approach to treating atopic dermatitisBiomarker
- 1mo agoEVMNEvommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 CongressBusiness WireEvommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced
- 2mo agoEVMNEvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic DermatitisBusiness Wire- Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated - EVO301, the Company’s IL-18BP fusion protein,
- 3mo agoEVMNEvommune Reports Second Quarter 2026 Financial Results and Provides Business HighlightsBusiness Wire‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027 ‑ EVO301 full
- 3mo agoEVMNEvommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine ProphylaxisBusiness Wire‑ MRGPRX2 receptor expressed in human trigeminal neurons and meningeal mast cells, the two key disease-relevant tissues in migraine biology ‑ EVO756 designed to inhibit three key neuropeptides (PACAP, VIP, Substance
- 4mo agoEVMNEvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous UrticariaBusiness Wire- Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks- Evommune to continue development of EVO756 in Atopic Dermatitis and MigraineEvommune, Inc.
- 6mo agoEVMNEvommune Reports First Quarter 2026 Financial Results and Provides Business HighlightsBusiness Wire‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials ‑ Phase 2b clinical trial
- 7mo agoEVMNEvommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in MigraineBusiness WireCompany to showcase expansion opportunity for EVO756 (MRGPRX2 Antagonist) into third indication of migraine prophylaxis; Phase 2b study to initiate in 3Q26 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a
- 8mo agoEVMNEvommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business HighlightsBusiness Wire– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26
- 9mo agoEVMNEvommune Announces $125 Million Private PlacementBusiness WireEvommune, Inc. ("Evommune" or the "Company") (NYSE:EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has
- 9mo agoEVMNEvommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic DermatitisBusiness Wire- Trial met primary efficacy endpoint at week 12 - EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo - 33% placebo-adjusted improvement in EASI at week 12 - 23%
- 11mo agoEVMNEvommune Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized to deliver on key milestones following
- 1y agoEVMNARWNYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin TradingPR NewswireThe New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for ...